aTyr Pharma redesigns Phase 3 trial for efzofitimod after FDA feedback, targets narrower patient group
Filed May 11, 2026 · Period ending May 11, 2026 · ~1 min read
4 material changes detected in this filing.
Create a free account to read the full summary — it takes 30 seconds.
Partner
Trade ATYR commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Generated by AI · Jun 2, 2026 4:24 PM